Latest Ratios: P/E Ratio -0.8x · EV/EBITDA N/A · ROE N/A. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $60M | $27M | $99M | $55M | $259M | $331M | $52M | $27M | $56M | $33M | $73M |
| Enterprise Value | $82M | $49M | $114M | $67M | $252M | $329M | $49M | $34M | $76M | $48M | $80M |
| P/E Ratio → | -0.82 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 42.49 | 19.10 | — | — | — | — | — | 3.33 | 17.98 | 8.64 | 24.55 |
| P/B Ratio | — | — | — | — | 29.62 | 71.91 | 18.49 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 34.75 | — | — | — | — | — | 4.18 | 24.52 | 12.64 | 26.69 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.5% | 46.5% | — | — | — | — | — | -192.2% | — | — | — |
| Operating Margin | -4744.3% | -4744.3% | — | — | — | — | — | -445.6% | -960.0% | -941.2% | -1723.1% |
| Net Profit Margin | -4416.2% | -4416.2% | — | — | — | — | — | -423.8% | -974.5% | -1019.1% | -1788.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -990.0% | -1430.5% | -1247.0% | — | — | — | — |
| ROA | -263.4% | -263.4% | -246.6% | -193.9% | -257.3% | -249.9% | -191.2% | -175.2% | -139.9% | -174.8% | -301.9% |
| ROIC | — | — | — | -342086.3% | -2184.8% | -6926.2% | — | — | — | — | -3267.2% |
| ROCE | — | — | — | — | -507.5% | -519.8% | -10697.2% | — | — | — | -1570.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 1.25 | 2.58 | 3.11 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -0.74 | -0.56 | -1.32 | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -224.96 | -224.96 | -22.87 | -36.81 | -43.42 | -55.26 | -20.93 | -9.94 | -7.67 | -5.82 | -27.73 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.38 | 0.38 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 | 0.67 | 0.10 | 0.14 | 0.28 |
| Quick Ratio | 0.31 | 0.31 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 | 0.67 | 0.10 | 0.14 | 0.28 |
| Cash Ratio | 0.18 | 0.18 | 0.35 | 0.50 | 0.88 | 2.14 | 0.79 | 0.40 | 0.05 | 0.11 | 0.12 |
| Asset Turnover | — | 0.08 | — | — | — | — | — | 0.48 | 0.14 | 0.18 | 0.13 |
| Inventory Turnover | 0.23 | 0.23 | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 384.99 | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 100.0% | 100.0% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 0.0% |
| Shares Outstanding | — | $25M | $19M | $13M | $11M | $8M | $4M | $909591 | $354026 | $150261 | $107581 |
Binary Regulatory and Liquidity
As reported in recent financial filings, OTLK trades at a price-to-sales ratio of 49.77, a figure that appears disconnected from fundamental performance and instead reflects the market's speculative pricing of the company's potential transition from a pre-commercial entity to an FDA-approved ophthalmic drug manufacturer.
The elevated P/S multiple is largely an artifact of minimal, non-recurring licensing revenue rather than a reflection of sustainable market demand. Investors should monitor this valuation with caution, as it implies a high growth expectation that remains entirely contingent upon the successful completion of the NORSE EIGHT clinical trial.
Based on the provided quarterly data, the company's operating margin of -110.1% in 2026Q2 highlights the extreme cost intensity of clinical development, which consistently overwhelms the sporadic and non-recurring revenue streams recognized from international licensing partnerships during this pre-commercial phase of the business cycle.
The volatility in reported margins, including anomalous positive spikes in previous quarters, suggests that non-operating items and accounting adjustments are significantly distorting the true earning power of the firm. True profitability remains non-existent, and investors should focus on the cash burn rate rather than accounting-based margin metrics.
According to recent SEC filings, the company's current ratio of 0.54 indicates a severe liquidity constraint, suggesting that OTLK may struggle to meet its short-term obligations without immediate access to additional capital to fund the ongoing clinical trial requirements and general corporate overhead.
The quick ratio of 0.45 further underscores the lack of liquid assets available to cover current liabilities, leaving the company highly vulnerable to any further regulatory delays. This liquidity position warrants close investigation, as it suggests an imminent need for dilutive financing to maintain operations.
As noted in historical financial statements, the use of P/E or EV/EBITDA ratios for OTLK is fundamentally flawed, as these metrics obscure the reality that the company is currently a pre-revenue, clinical-stage entity where traditional earnings-based valuation models are entirely inapplicable to the business model.
Analysts should instead prioritize a 'cash-to-milestone' analysis, which evaluates the company's remaining runway against the time required to reach the next regulatory catalyst. Relying on earnings multiples in this context may lead to a significant mispricing of the firm's actual risk-adjusted terminal value.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OTLK stock.
Outlook Therapeutics, Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.
Based on historical data, Outlook Therapeutics, Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Outlook Therapeutics, Inc. has 46.5% gross margin and -4744.3% operating margin.